Kenneth Fong
Fondateur chez Kenson Ventures LLC
Profil
Kenneth Fong, Ph.D., is the Chairman of Kenson Ventures, LLC.
Kenson specializes in venture financing and strategic consulting to biotech companies.
As of January 2016, Kenson has investments that mostly fall into 3 major categories: a) Innovative Research Tools, b) Platform Technologies, and c) Drug Development.
Prior to founding Kenson, Dr. Fong is the founder and former CEO of CLONTECH Laboratories, that was acquired by Becton Dickinson (BD) in late 1999.
CLONTECH is the leader in the Molecular/Cell Biology market and in the last 4 years before its acquisition, the company had experienced an average growth rate of 36% a year.
The company also had 48 consecutive quarters of double-digit growth and profits.
In 1994, 1995, 1998, and 1999, CLONTECH was selected as one of the fastest-growing companies in the San Francisco Bay Area.
Dr. Fong's past experience is best suited to young companies and those desire to grow more rapidly.
He is also adept at crafting development strategy and realistic implementation plan to promote the long-term growth of company.
Dr. Fong obtained his Ph.D.
from Indiana University.
Postes actifs de Kenneth Fong
| Sociétés | Poste | Début |
|---|---|---|
Kenson Ventures LLC
 Kenson Ventures LLC Investment ManagersFinance Kenson Ventures LLC (Kenson Ventures) is a venture capital firm founded in 1999 by Kenneth Fong. The firm is headquartered in in Palo Alto, California. | Fondateur | 29/06/2010 |
Epitomics, Inc.
 Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Directeur/Membre du Conseil | - |
DiagCor Bioscience, Inc. Ltd.
 DiagCor Bioscience, Inc. Ltd. Medical SpecialtiesHealth Technology DiagCor Bioscience, Inc. Ltd. develops and commercializes in vitro diagnostic kits and instruments. It offers a complete platform for commercial and clinical MDx diagnosis. The firm serves clinical diagnostic services markets in Latin America, Europe, Middle East and South East Asia. Its products include R2-M flow-through hybridization system, FT-PRO flow-through hybridization system, capture-PRO image capture system, Taigen VacEZor and FT-PRO auto system. The company was founded by Joseph Wing On Tam in 2006 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | - |
System Biosciences LLC
 System Biosciences LLC Miscellaneous Commercial ServicesCommercial Services System Biosciences LLC develops proprietary siRNA and microRNA technologies. Its products include lentiviral technology, genome engineering, molecular tools, stem cell research, exosome research, microrna research and immunology. The company was founded by Kenneth Fong in July 2002 and is headquartered in Palo Alto, CA. | Fondateur | 01/07/2002 |
Committee of 100
 Committee of 100 Investment Trusts/Mutual FundsMiscellaneous Committee of 100 provides grant making services. The non-profit company is based in New York, NY. The company was founded in 1988 by Henry Alfred Kissinger, Ieoh Ming Pei. | Directeur/Membre du Conseil | 01/01/1997 |
Anciens postes connus de Kenneth Fong
| Sociétés | Poste | Fin |
|---|---|---|
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Président | 29/06/2022 |
| TURG POIN | Directeur/Membre du Conseil | 01/12/2018 |
Takara Bio USA, Inc.
 Takara Bio USA, Inc. Medical/Nursing ServicesHealth Services Takara Bio USA, Inc. helps to accelerate the discovery process by providing pioneering tools that enable researchers to ask new questions and investigate ever more complex systems than was previously possible. With more than 5,000 literature citations, its innovative products and services continue to facilitate advancement in areas such as genomics, cancer research, apoptosis, cytogenetics, developmental genetics, cellular physiology, pharmocogenetics, and neurobiology. | Directeur Général | 31/12/1999 |
| APEXIGEN, INC. | Directeur/Membre du Conseil | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | - |
Formation de Kenneth Fong
| Indiana University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APEXIGEN, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Finance |
Kenson Ventures LLC
Kenson Ventures LLC Investment ManagersFinance Kenson Ventures LLC (Kenson Ventures) is a venture capital firm founded in 1999 by Kenneth Fong. The firm is headquartered in in Palo Alto, California. | Finance |
Takara Bio USA, Inc.
Takara Bio USA, Inc. Medical/Nursing ServicesHealth Services Takara Bio USA, Inc. helps to accelerate the discovery process by providing pioneering tools that enable researchers to ask new questions and investigate ever more complex systems than was previously possible. With more than 5,000 literature citations, its innovative products and services continue to facilitate advancement in areas such as genomics, cancer research, apoptosis, cytogenetics, developmental genetics, cellular physiology, pharmocogenetics, and neurobiology. | Health Services |
Epitomics, Inc.
Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Health Technology |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Health Technology |
DiagCor Bioscience, Inc. Ltd.
DiagCor Bioscience, Inc. Ltd. Medical SpecialtiesHealth Technology DiagCor Bioscience, Inc. Ltd. develops and commercializes in vitro diagnostic kits and instruments. It offers a complete platform for commercial and clinical MDx diagnosis. The firm serves clinical diagnostic services markets in Latin America, Europe, Middle East and South East Asia. Its products include R2-M flow-through hybridization system, FT-PRO flow-through hybridization system, capture-PRO image capture system, Taigen VacEZor and FT-PRO auto system. The company was founded by Joseph Wing On Tam in 2006 and is headquartered in Hong Kong. | Health Technology |
System Biosciences LLC
System Biosciences LLC Miscellaneous Commercial ServicesCommercial Services System Biosciences LLC develops proprietary siRNA and microRNA technologies. Its products include lentiviral technology, genome engineering, molecular tools, stem cell research, exosome research, microrna research and immunology. The company was founded by Kenneth Fong in July 2002 and is headquartered in Palo Alto, CA. | Commercial Services |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Committee of 100
Committee of 100 Investment Trusts/Mutual FundsMiscellaneous Committee of 100 provides grant making services. The non-profit company is based in New York, NY. The company was founded in 1988 by Henry Alfred Kissinger, Ieoh Ming Pei. | Miscellaneous |
